Tags

Type your tag names separated by a space and hit enter

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Blood. 2020 05 21; 135(21):1912-1915.Blood

Links

PMC Free PDF
PMC Free Full Text
Publisher Full Text
linkinghub.elsevier.com
linkinghub.elsevier.com
ashpublications.org

Authors+Show Affiliations

Treon SP
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Castillo JJ
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Skarbnik AP
Lymphoproliferative Disorders Program, Novant Health, Charlotte, NC; and.
Soumerai JD
Department of Medicine, Harvard Medical School, Boston, MA. Massachusetts General Hospital, Boston, MA.
Ghobrial IM
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Guerrera ML
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Meid K
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
Yang G
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.

MeSH

AdenineAgammaglobulinaemia Tyrosine KinaseAgedBetacoronavirusCOVID-19Coronavirus InfectionsFemaleHumansLung InjuryMaleMiddle AgedPandemicsPiperidinesPneumonia, ViralProtein Kinase InhibitorsPyrazolesPyrimidinesSARS-CoV-2Waldenstrom Macroglobulinemia

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32302379

Citation

Treon, Steven P., et al. "The BTK Inhibitor Ibrutinib May Protect Against Pulmonary Injury in COVID-19-infected Patients." Blood, vol. 135, no. 21, 2020, pp. 1912-1915.
Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912-1915.
Treon, S. P., Castillo, J. J., Skarbnik, A. P., Soumerai, J. D., Ghobrial, I. M., Guerrera, M. L., Meid, K., & Yang, G. (2020). The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood, 135(21), 1912-1915. https://doi.org/10.1182/blood.2020006288
Treon SP, et al. The BTK Inhibitor Ibrutinib May Protect Against Pulmonary Injury in COVID-19-infected Patients. Blood. 2020 05 21;135(21):1912-1915. PubMed PMID: 32302379.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. AU - Treon,Steven P, AU - Castillo,Jorge J, AU - Skarbnik,Alan P, AU - Soumerai,Jacob D, AU - Ghobrial,Irene M, AU - Guerrera,Maria Luisa, AU - Meid,Kirsten, AU - Yang,Guang, PY - 2020/4/18/pubmed PY - 2020/6/2/medline PY - 2020/4/18/entrez SP - 1912 EP - 1915 JF - Blood JO - Blood VL - 135 IS - 21 SN - 1528-0020 UR - https://www.unboundmedicine.com/medline/citation/32302379/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-4971(20)62018-3 DB - PRIME DP - Unbound Medicine ER -